共 50 条
- [41] Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomasHAEMATOLOGICA, 2022, 107 (07) : 1608 - 1618Major, AjayKline, JustinKarrison, Theodore G.Fishkin, Paul A. S.Kimball, Amy S.Petrich, Adam M.Nattam, SreenivasaRao, KrishnaSleckman, Bethany G.Cohen, Kennethvan Besien, KoenRapoport, Aaron P.Smith, Sonali M.
- [42] High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I TrialBLOOD, 2015, 126 (23)Chihara, DaiOki, YasuhiroWestin, Jason R.Nastoupil, LorettaFayad, Luis E.Samaniego, FelipeWesson, EmilyRuben, CharnelleHorowitz, Sandra B.Feng, LeiGarg, NaveenAhmed, SairahKhouri, Issa F.Hosing, Chitra M.Romaguera, Jorge E.Fowler, NathanFanale, Michelle A.
- [43] A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphomaHAEMATOLOGICA, 2018, 103 (09) : E416 - E418Strati, PaoloChihara, DaiOki, YasuhiroFayad, Luis E.Fowler, NathanNastoupil, LorettaRomaguera, Jorge E.Samaniego, FelipeGarg, NaveenFeng, LeiWesson, Emily T.Ruben, Charnelle E.Stafford, Mildred D.Nieto, YagoKhouri, Issa F.Hosing, ChitraHorowitz, Sandra B.T-Kamble, RammurtiFanale, Michelle A.
- [44] Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell LymphomaBLOOD, 2011, 118 (21) : 272 - 272Coiffier, BertrandPro, BarbaraPrince, H. MilesFoss, Francine M.Sokol, LubomirGreenwood, MatthewCaballero, DoloresBorchmann, PeterMorschhauser, FranckWilhelm, MartinPinter-Brown, LaurenPadmanabhan, SwaminathanShustov, Andrei R.Nichols, JeanCarroll, SusanBalser, JohnHorwitz, Steven M.
- [45] Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialLANCET ONCOLOGY, 2012, 13 (07): : 716 - 723Wang, MichaelFayad, LuisWagner-Bartak, NicolausZhang, LiangHagemeister, FredrickNeelapu, Sattva S.Samaniego, FelipeMcLaughlin, PeterFanale, MichelleYounes, AnasCabanillas, FernandoFowler, NathanNewberry, Kate J.Sun, LuhongYoung, Ken H.Champlin, RichardKwak, LarryFeng, LeiBadillo, MariaBejarano, MariaHartig, KimberlyChen, WendyChen, YimingByrne, CatrionaBell, NedaZeldis, JeromeRomaguera, Jorge
- [46] Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesJournal of Hematology & Oncology, 7Bertrand CoiffierBarbara ProH Miles PrinceFrancine FossLubomir SokolMatthew GreenwoodDolores CaballeroFranck MorschhauserMartin WilhelmLauren Pinter-BrownSwaminathan Padmanabhan IyerAndrei ShustovTina NielsenJean NicholsJulie WolfsonBarbara BalserSteven Horwitz
- [47] Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesJOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7Coiffier, BertrandPro, BarbaraPrince, H. MilesFoss, FrancineSokol, LubomirGreenwood, MatthewCaballero, DoloresMorschhauser, FranckWilhelm, MartinPinter-Brown, LaurenIyer, Swaminathan PadmanabhanShustov, AndreiNielsen, TinaNichols, JeanWolfson, JulieBalser, BarbaraHorwitz, Steven
- [48] Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I TrialCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 139 - 146Kambhampati, SwethaFakhri, BitaAi, Weiyun Z.Kaplan, Lawrence D.Tuscano, Joseph M.Wieduwilt, Matthew J.Sudhindra, AkshayCavallone, ErikaReiner, JesikaAoun, CharlieCastillo, MiguelMartinelli, MichelleTa, TeresaLe, DiemPadilla, MichelleCrawford, ErikaAndreadis, Charalambos B.
- [49] Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Malignancies (R/R TCM)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S523 - S523Gordon, MaxMiljkovic, MilosNg, SamuelLakhotia, RahulMelani, ChristopherConlon, KevinPhelan, JamesBryant, BonitaYee, LauraPittaluga, StefaniaJaffe, ElaineStaudt, LouisWilson, WyndhamRoschewski, Mark
- [50] Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialNATURE MEDICINE, 2024, : 3778 - 3778Horwitz, Steven M.Nirmal, Ajit J.Rahman, JahanXu, RanDrill, EstherGalasso, NatashaGanesan, NivethaDavey, TheresaHancock, HelenPerez, LeslieMaccaro, CatherineBahgat, AlexandraMarzouk, EvanCathcart, ElizabethMoskowitz, AlisonNoy, ArielaKumar, AnitaJacobsen, EricFisher, David C.Mehta-Shah, NehaKim, Youn H.Khodadoust, MichaelKotlov, NikitaNikitina, AnastasiaKudryashova, OlgaZubareva, ValeriaZornikova, KseniaShin, NaraSorokina, MariaDegryse, SandrinePostovalova, EkaterinaBagaev, AleksanderHosszu, KingaMcavoy, DevinBoelens, Jaap J.Wu, WenchaoCiantra, ZoeAppelt, Jackson W.Trevisani, ChristopherAmaka, SamWeinstock, David M.Vardhana, Santosha A.